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Poster Presentation Abstracts 131and can recover to its original shape when compression ratio is less than 80%
which will be very attractive for bone tissue engineering. SEM analysis shows
that the pores in the hydrogel was uniformly present and highly interconnected
which is very important for nutrients transplantation. XRD image indicates that
both polmers and clay were well distributed. Adding macromolecular crosslinker
(PEGDA) into the system can not only increase the biocompatibility but also
improve the bone formation compared with the nanocomposite hydrogel
without PEGDA.
Discussion and Conclusion: A novel nanocomposite hydrogels composed of exfoli-
ated clay showed attractive fracture strain up to 5000% and good compression
strength. This kind of hydrogel was synthesized by in situ photo-polymerization
of monomer in the presence of clay, acrylic acid derivatives and macromolecular
crosslinker (PEGDA). More attractive part is that the obtained nanocomposite
hydrogel has good biocompatibility and can accelerate bone formation. So that
we will explore why this kind of hydrogel can accelerate bone formation and
find out the best PEGDA molecular weight, clay content and solid content for
bone formation.
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Introduction: Articular cartilage is an anisotropic structure with a zonal design and
consists of surface or superficial, middle, and deep zones. Superficial zone protein
(SZP)/lubricin/PRG4 functions as a boundary lubricant in articular cartilage to
decrease friction and wear. (Reference 1, 2) As articular cartilage lubrication is
critical for normal joint function, the accumulation of SZP at the surface of carti-
lage is important for joint homeostasis. Recently, a heterocyclic compound called
kartogenin (KGN) was found to induce chondrogenic differentiation and enhance
mRNA expression of lubricin. (Reference. 3) The objective of this study was to
determine whether KGN can stimulate synthesis of SZP in superficial zone articular
chondrocytes and synoviocytes.
Subjects and Methods: We investigated the effects of KGN and transforming
growth factor-b1 (TGF-b1) on articular cartilage and synovium of the bovine
knee joint by evaluating SZP secretion by enzyme-linked immunosorbent assay
analysis. Monolayer, micromass, and explant cultures of articular cartilage, and
monolayer culture of synoviocytes, were treated with KGN and TGF-b1. Explant
was also treated with KGN and IL-1b to evaluate the anti-catabolic effect of
KGN. SZP accumulation in the medium was evaluated and mRNA expression was
measured through quantitative polymerase chain reaction.
Results: TGF-b1 stimulated SZP secretion by superficial zone chondrocytes in
monolayer, explant, and micromass cultures as expected. In addition, SZP secre-
tion was inhibited by IL-1b in explant cultures, and enhanced by TGF-b1 in synovio-
cyte monolayer cultures. Although KGN elicited a 1.2-fold increase in SZP mRNA
expression in combination with TGF-b1, KGN neither stimulated any significant in-
creases in SZP synthesis nor prevented catabolic decreases in SZP production from
IL-1b.
Discussion and Conclusion: These data suggest that the chondrogenic effects of
KGN depend on cellular phenotype and differentiation status, as KGN did not alter
SZP synthesis in differentiated, superficial zone articular chondrocytes. However,
these apparent differences between progenitor and differentiated cell types in
response to KGN merit additional investigation since important new, mechanistic
insights into the effects of KGN may be revealed.
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Background: Giant cell tumor of bone (GCT) is a common neoplasm in Chinese pa-
tients, constituting 20% of all benign bone tumors. The stromal cells of GCT are
widely accepted to be the primary neoplastic cells, and originate from mesen-
chymal stem cells (MSC). Since GCT stromal cells could be induced to be mature
osteoblasts, our research team has proposed the differentiation therapy of GCT
stromal cells. It is noteworthy that rapamycin and simvastatin have been shown
to induce osteogenic differentiation in a number of tumor types, and they are
FDA-approved drugs and have been safely used in patients for decades. Therefore,
we reasoned that they may be developed as adjuvant therapy agents for GCT.
Subjects and Methods: We investigated the effects of rapamycin and simvastatin
on cell viability, proliferation and osteoblastic differentiation in GCT stromal cells
in vitro. Cell viability was assessed using MTT assay, whereas, cell proliferation by
BrdU assay. The markers for assessing the re-differentiation of GCT stromal cells
are ALP, RUNX2, and OCN, and the mRNA level of those markers were detected
by real-time PCR.
Results: Rapamycin decreased the cell viability and proliferation of GCT stromal
cells significantly at 0.05 mM but no further inhibition was observed when
increasing the dose of the drug up to 5 mM. Whereas, simvastatin showed a
dose-dependent inhibition on cell viability and proliferation in GCT stromal cells.
Moreover, the important osteoblastic markers RUNX2 and osteocalcin were up-
regulated by both drugs.
Discussion and Conclusion: Rapamycin and simvastatin inhibited cell viability, and
proliferation of GCT stromal cells. They also stimulated RUNX2 and osteocalcin
gene expression, and may induce differentiation of the tumor cells. Previous
studies have shown that simvastatin induces osteoblast differentiation by moni-
toring Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway
(Yamashita et al. 2008), whereas, rapamycin stimulates the osteoblastic differen-
tiation of human embryonic stem cells by blocking the mammalian target of rapa-
mycin (mTOR) pathway and activating the BMP/Smad pathway (Lee et al. 2010).
The possibility of using rapamycin and simvastatin to promote the differentiation
of GCT stromal cells into mature osteoblasts is appealing. Such a strategy has the
dual advantage of preventing further bone destruction as a result of the osteolytic
tumor while simultaneously promoting bone formation as the neoplastic cells are
differentiated into mature osteoblasts. The mature osteoblasts will eventually un-
dergo apoptosis. It will stop the tumor growth and thus reduce bone resorption.
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EXPRESSION OF GLYPICAN-3 AND PERIOSTIN IN MUSCULOSKELETAL TUMOR
PATIENTS
Thamonwan Woraruthai, Sittisak Honsawek
Chulalongkorn University, Thailand
Background: Glypican-3 (GPC-3) is an extracellular matrix that functions in cell
adhesion, migration and invasion during cell proliferation. It can induce abnormal
cells to apoptosis. Additionally, periostin (POSTN) is also extracellular matrix that
involve in tissue development and regeneration. This gene can bind to integrin for
supporting adhesion and migration of epithelial cells. However, GPC-3 and POSTN
expressions in soft tissue sarcoma remain unclear. The purpose of this study was to
examine expression of GPC3 and POSTN in neoplastic and non-neoplastic adjacent
tissues of musculoskeletal tumor patients.
Subjects and Methods: This research was conducted a cross-sectional study.
Twenty musculoskeletal tumor patients who had liposacroma, osteosarcoma, li-
poma, giant cell tumor and chondroma were enrolled in this study. The GPC-3
